| My Account | Subscribe | Contact Us | Help |
Even drops in the bucket make a difference
It has been 22 years since Air Canada pilot Steve Steele was grounded with type 1
A traveling couple tries to stick to low carbs
Here’s something to make you sit up and take notice (maybe 100 times a night): 23 percent of type 2s have obstructive sleep apnea.
The must-have resource for physicians, educators and medical professionals who focus on the treatment of diabetes.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
Latest Type 2 Issues Articles
Not Just Cholesterol-Lowing Benefits
A South Carolina study indicates that simvastatin (Zocor), an oral “statin” lipid-lowering drug is a potentially beneficial treatment for the inflammatory reaction associated with atherosclerosis.
Twenty-six patients with type 2 diabetes participated in the study. They were started on a lipid-lowering diet and encouraged to exercise in addition to receiving Zocor treatment that was adjusted until LDL cholesterol levels reached 100 mg/dl or lower.
A1C levels remained constant throughout the study. There was a highly significant reduction in blood levels of immune complexes containing modified lipoproteins after three to six months of treatment with Zocor.
Levels returned to baseline after Zocor use was discontinued.
Researchers note this may represent an additional mechanism for the reduced incidence of cardiovascular events in patients treated with Zocor.
—Diabetes Care, April 2004
147 comments - 29 Nov 2007
106 comments - 22 Sep 2008
82 comments - 14 Aug 2008
52 comments - 18 Jan 2008
Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register..
Register your Diabetes Health Username here.
Have Your Say...